Arcutis Biotherapeutics, Inc.
ARQT
$22.91
$0.673.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 28.51% | 21.74% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 30.52% | 21.74% | |||
| Cost of Revenue | 34.58% | 15.92% | |||
| Gross Profit | 30.13% | 22.32% | |||
| SG&A Expenses | 26.56% | -9.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.52% | -5.64% | |||
| Operating Income | 115.66% | 158.35% | |||
| Income Before Tax | 138.52% | 148.19% | |||
| Income Tax Expenses | 487.50% | -76.61% | |||
| Earnings from Continuing Operations | 134.75% | 146.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 134.75% | 146.64% | |||
| EBIT | 115.66% | 158.35% | |||
| EBITDA | 108.52% | 164.00% | |||
| EPS Basic | 133.39% | 146.44% | |||
| Normalized Basic EPS | 137.33% | 147.97% | |||
| EPS Diluted | 113.77% | 146.44% | |||
| Normalized Diluted EPS | 133.81% | 146.01% | |||
| Average Basic Shares Outstanding | 0.49% | 0.49% | |||
| Average Diluted Shares Outstanding | 2.07% | 4.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||